Study of Ravulizumab in Pediatric Participants With HSCT-TMA

Completed · Phase 3

Conditions studied: Thrombotic Microangiopathy

In brief

This study will evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of ravulizumab administered by intravenous infusion to pediatric participants, from 1 month to \< 18 years of age, with HSCT-TMA. The treatment period is 26 weeks, followed by a 26-week off-treatment follow-up period.

Key facts

Study ID: NCT04557735
Run by: Alexion Pharmaceuticals, Inc.
People needed: 41
Starts: 2020-12-07
Expected to finish: 2025-05-27
Last updated by the study team: 2026-01-12

Who can join

Age: any, up to 17. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

≥ 28 days of age up to < 18 years of age at the time of signing the informed consent.
Received HSCT within the past 12 months.
Diagnosis of TMA that persists for at least 72 hours after initial management of any triggering agent/condition.
A TMA diagnosis based on meeting the laboratory-based criteria during the Screening Period and/or ≤14 days prior to the Screening Period.
Body weight ≥ 5 kilograms at Screening or ≤7 days prior to the start of the Screening Period (date of consent).
Female participants of childbearing potential and male participants with female partners of childbearing potential must use highly effective contraception.
Participants must be vaccinated against meningococcal infections if clinically feasible. Participants who cannot receive meningococcal vaccine should receive antibiotic prophylaxis. Participants <18 years of age must be re-vaccinated against Haemophilus influenzae type b (Hib) and Streptococcus pneumoniae if clinically feasible.
Participants or their legally authorized representative must be capable of giving signed informed consent or assent.

You may not qualify if…

Thrombotic thrombocytopenic purpura (TTP) evidenced by ADAMTS13 deficiency.
Known Shiga toxin-related hemolytic uremic syndrome as demonstrated by positive test.
Positive direct Coombs test indicative of a clinically significant immune-mediated hemolysis not due to TMA.
Clinical diagnosis of disseminated intravascular coagulation (DIC).
Known bone marrow/graft failure for the current HSCT.
Diagnosis of veno-occlusive disease (VOD) which is unresolved at the time of Screening.
Human immunodeficiency virus (HIV) infection.
Unresolved meningococcal disease.
Presence of sepsis requiring vasopressor support.
Pregnancy or breastfeeding.
Hypersensitivity to murine proteins or to 1 of the excipients of Ravulizumab.
Any ongoing or history of medical or psychological conditions unrelated to HSCT-TMA that could increase the risk to the participant or confound the outcome of the study.
Respiratory failure requiring mechanical ventilation.
Previously or currently treated with a complement inhibitor.
Participation in an interventional treatment study of any therapy for TMA.

Where it is running

Research Site — Tucson, Arizona, United States
Research Site — Aurora, Colorado, United States
Research Site — Atlanta, Georgia, United States
Research Site — Chicago, Illinois, United States
Research Site — Portland, Oregon, United States
Research Site — Dallas, Texas, United States
Research Site — Salt Lake City, Utah, United States
Research Site — Madison, Wisconsin, United States
Research Site — Haifa, Israel
Research Site — Jerusalem, Israel
Research Site — Petah Tikva, Israel
Research Site — Ramat Gan, Israel
Research Site — Roma, Italy
Research Site — Fukushima, Japan
Research Site — Kobe, Japan
Research Site — Nagoya, Japan
Research Site — Osaka, Japan
Research Site — Seoul, South Korea
Research Site — Seoul, South Korea
Research Site — Barcelona, Spain
Research Site — Esplugues de Llobregat, Spain
Research Site — Madrid, Spain
Research Site — Salamanca, Spain
Research Site — Birmingham, United Kingdom
Research Site — Bristol, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.